pp32 is a lineage-independent nuclear phosphoprotein expressed at high levels in stem-like self-renewing cell populations and neoplastic cells, but not in terminally differentiated cells. Expression of pp32 appears to increase with malignant potential in tumors such as prostate cancer. pp32 has a leucine zipper and an acidic domain, suggesting interaction with other nuclear elements. Previous work under this grant established three functional activities for pp32 which may relate to its role in self-renewing and neoplastic cells: pp32 suppresses transformation of fibroblasts cotransformed by ras with myc, jun, mutant p53, or E1a; pp32 modulates cellular sensitivity to drug- induced programmed cell death; and pp32 may modulate nuclear shape and size. Studies proposed for the next funding period seek to understand structural- functional relationships in pp32 and relate these to its increased expression in neoplasia. The hypotheses to be tested are: (1) that pp32 functions are associated with discrete elements with pp32 sequence; (2) that one or more functionally significant pp32 sequence elements or motifs will govern the interaction of pp32 with one or more additional protein molecules; and (3) that interaction of pp32 with one or more additional protein molecules is obligatory for pp32 to confer resistance to transformation or apoptosis, to modulate nuclear morphology, or potentially modulate transcriptional activity. The detailed aims are:
(Aim one) to determine structure-function relationships in pp32 by mutational analysis through truncation, deletion, and point mutation with subsequent testing for the ability to suppress transformation, protect against programmed cell death, and modulate nuclear size;
(Aim two) to identify and characterize unknown molecules which bind to pp32 and to test the ability of known molecules such as fos, jun myc, e1a and p53 using a two-hybrid system, immunoprecipitation, and, for unknown molecules only, affinity chromatography;
and (Aim three) to characterize the regulation of pp32 expression in normal and neoplastic cells in primary cultures of normal and neoplastic cells, normal cell lines, and neoplastic cell lines studied to determine the critical factors which regulate pp32 levels examining transcriptional activation, mRNA half-lives, protein synthetic rates, and protein half-lives.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA054404-07
Application #
2748727
Study Section
Pathology B Study Section (PTHB)
Program Officer
Gallahan, Daniel L
Project Start
1992-03-01
Project End
2002-02-28
Budget Start
1998-08-01
Budget End
2002-02-28
Support Year
7
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Pathology
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Griggs, Jennifer J; Hamilton, Ann S; Schwartz, Kendra L et al. (2017) Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample. Breast Cancer Res Treat 161:375-384
Janz, Nancy K; Li, Yun; Beesley, Lauren J et al. (2016) Worry about recurrence in a multi-ethnic population of breast cancer survivors and their partners. Support Care Cancer 24:4669-78
Parise, Carol; Caggiano, Vincent (2016) Breast Cancer Mortality among Asian-American Women in California: Variation according to Ethnicity and Tumor Subtype. J Breast Cancer 19:112-21
Steffen, Laurie E; Boucher, Kenneth M; Damron, Barbara H et al. (2015) Efficacy of a Telehealth Intervention on Colonoscopy Uptake When Cost Is a Barrier: The Family CARE Cluster Randomized Controlled Trial. Cancer Epidemiol Biomarkers Prev 24:1311-8
DeRouen, Mindy C; Smith, Ashley Wilder; Tao, Li et al. (2015) Cancer-related information needs and cancer's impact on control over life influence health-related quality of life among adolescents and young adults with cancer. Psychooncology 24:1104-15
Jagsi, Reshma; Griffith, Kent A; Kurian, Allison W et al. (2015) Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer. J Clin Oncol 33:1584-91
Jagsi, Reshma; Li, Yun; Morrow, Monica et al. (2015) Patient-reported Quality of Life and Satisfaction With Cosmetic Outcomes After Breast Conservation and Mastectomy With and Without Reconstruction: Results of a Survey of Breast Cancer Survivors. Ann Surg 261:1198-206
Parsons, Helen M; Harlan, Linda C; Stevens, Jennifer L et al. (2014) Treatment of small cell lung cancer in academic and community settings: factors associated with receiving standard therapy and survival. Cancer J 20:97-104
Friese, Christopher R; Martinez, Kathryn A; Abrahamse, Paul et al. (2014) Providers of follow-up care in a population-based sample of breast cancer survivors. Breast Cancer Res Treat 144:179-84
Jagsi, Reshma; Hawley, Sarah T; Abrahamse, Paul et al. (2014) Impact of adjuvant chemotherapy on long-term employment of survivors of early-stage breast cancer. Cancer 120:1854-62

Showing the most recent 10 out of 60 publications